These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 37620807)

  • 1. Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis.
    Rossing P; Bain SC; Bosch-Traberg H; Sokareva E; Heerspink HJL; Rasmussen S; Mellbin LG
    Cardiovasc Diabetol; 2023 Aug; 22(1):220. PubMed ID: 37620807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials.
    Mann JFE; Hansen T; Idorn T; Leiter LA; Marso SP; Rossing P; Seufert J; Tadayon S; Vilsbøll T
    Lancet Diabetes Endocrinol; 2020 Nov; 8(11):880-893. PubMed ID: 32971040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials.
    Husain M; Bain SC; Holst AG; Mark T; Rasmussen S; Lingvay I
    Cardiovasc Diabetol; 2020 Sep; 19(1):156. PubMed ID: 32998732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo.
    Tuttle KR; Bosch-Traberg H; Cherney DZI; Hadjadj S; Lawson J; Mosenzon O; Rasmussen S; Bain SC
    Kidney Int; 2023 Apr; 103(4):772-781. PubMed ID: 36738891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6.
    Husain M; Consoli A; De Remigis A; Pettersson Meyer AS; Rasmussen S; Bain S
    Cardiovasc Diabetol; 2022 Apr; 21(1):64. PubMed ID: 35484580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes: Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6.
    Strain WD; Frenkel O; James MA; Leiter LA; Rasmussen S; Rothwell PM; Sejersten Ripa M; Truelsen TC; Husain M
    Stroke; 2022 Sep; 53(9):2749-2757. PubMed ID: 35582947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial.
    Leiter LA; Bain SC; Hramiak I; Jódar E; Madsbad S; Gondolf T; Hansen T; Holst I; Lingvay I
    Cardiovasc Diabetol; 2019 Jun; 18(1):73. PubMed ID: 31167654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
    Zelniker TA; Raz I; Mosenzon O; Dwyer JP; Heerspink HHJL; Cahn A; Goodrich EL; Im K; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Gause-Nilsson I; Langkilde AM; Sabatine MS; Wiviott SD
    JAMA Cardiol; 2021 Jul; 6(7):801-810. PubMed ID: 33851953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemoglobin A1c Reduction With the GLP-1 Receptor Agonist Semaglutide Is Independent of Baseline eGFR:
    Cherney DZI; Hadjadj S; Lawson J; Mosenzon O; Tuttle K; Vrhnjak B; Rasmussen S; Bain SC
    Kidney Int Rep; 2022 Nov; 7(11):2345-2355. PubMed ID: 36531884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The kidney and cardiovascular outcome trials.
    Bloomgarden Z
    J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function: A
    Waijer SW; Gansevoort RT; Bakris GL; Correa-Rotter R; Hou FF; Kohan DE; Kitzman DW; Makino H; McMurray JJV; Perkovic V; Tobe S; Parving HH; de Zeeuw D; Heerspink HJL
    Clin J Am Soc Nephrol; 2021 Dec; 16(12):1824-1832. PubMed ID: 34853062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk.
    Husain M; Bain SC; Jeppesen OK; Lingvay I; Sørrig R; Treppendahl MB; Vilsbøll T
    Diabetes Obes Metab; 2020 Mar; 22(3):442-451. PubMed ID: 31903692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of semaglutide on kidney function across different levels of baseline HbA1c, blood pressure, body weight and albuminuria in SUSTAIN 6 and PIONEER 6.
    Apperloo EM; Cherney DZI; Kuhlman AB; Mann JFE; Rasmussen S; Rossing P; Tuttle KR; Vrhnjak B; Heerspink HJL
    Nephrol Dial Transplant; 2024 Jul; ():. PubMed ID: 38955363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND.
    Konig M; Riddle MC; Colhoun HM; Branch KR; Atisso CM; Lakshmanan MC; Mody R; Raha S; Gerstein HC
    Cardiovasc Diabetol; 2021 Sep; 20(1):194. PubMed ID: 34563178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease.
    Rossing P; Baeres FMM; Bakris G; Bosch-Traberg H; Gislum M; Gough SCL; Idorn T; Lawson J; Mahaffey KW; Mann JFE; Mersebach H; Perkovic V; Tuttle K; Pratley R
    Nephrol Dial Transplant; 2023 Aug; 38(9):2041-2051. PubMed ID: 36651820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis.
    Jardine M; Zhou Z; Lambers Heerspink HJ; Hockham C; Li Q; Agarwal R; Bakris GL; Cannon CP; Charytan DM; Greene T; Levin A; Li JW; Neuen BL; Neal B; Oh R; Oshima M; Pollock C; Wheeler DC; de Zeeuw D; Zhang H; Zinman B; Mahaffey KW; Perkovic V
    Clin J Am Soc Nephrol; 2021 Mar; 16(3):384-395. PubMed ID: 33619120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics predicting the efficacy of SGLT-2 inhibitors versus GLP-1 receptor agonists on major adverse cardiovascular events in type 2 diabetes mellitus: a meta-analysis study.
    Sohn M; Dietrich JW; Nauck MA; Lim S
    Cardiovasc Diabetol; 2023 Jun; 22(1):153. PubMed ID: 37381019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
    Perkovic V; Tuttle KR; Rossing P; Mahaffey KW; Mann JFE; Bakris G; Baeres FMM; Idorn T; Bosch-Traberg H; Lausvig NL; Pratley R;
    N Engl J Med; 2024 Jul; 391(2):109-121. PubMed ID: 38785209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
    Cherney DZI; Zinman B; Inzucchi SE; Koitka-Weber A; Mattheus M; von Eynatten M; Wanner C
    Lancet Diabetes Endocrinol; 2017 Aug; 5(8):610-621. PubMed ID: 28666775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular and renal outcomes with varying degrees of kidney disease in high-risk people with type 2 diabetes: An epidemiological analysis of data from the AMPLITUDE-O trial.
    Gerstein HC; Mian R; Ramasundarahettige C; Branch KRH; Del Prato S; Lam CSP; Lopes RD; Pratley R; Rosenstock J; Sattar N
    Diabetes Obes Metab; 2024 Apr; 26(4):1216-1223. PubMed ID: 38116691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.